Purpose: Bladder cancer recurrence following cystectomy remains a significant cause of bladder cancer specific mortality. Residual cancer cells contribute to cancer recurrence due to tumor spillage or undetectable preexisting micrometastatic tumor clones. We detected and quantified residual cancer cells in pelvic washing using ultradeep targeted sequencing. We compared the levels of residual cancer cells with clinical variables and cancer recurrence. Materials and Methods: The primary tumor specimen was available in 17 patients who underwent robot-assisted radical cystectomy. All tumors had negative surgical margins. Pelvic washes and blood were collected intraoperatively before and after robot-assisted radical cystectomy, after pelvic lymph node dissection and in the suction fluid collected during the procedure. Two-step sequencing, including whole exome sequencing followed by ultradeep targeted sequencing (Â greater than 50,000), was done to quantify residual cancer cells in each sample. Eight patients were excluded from study due to sample quality issues. The final analysis cohort comprised 9 patients. The residual cancer cell level was quantified for each sample as the relative cancer cell fraction and compared between time points. The peak relative cancer cell fraction of each patient was correlated with clinical and pathological variables. Results: Residual cancer cells were detected in approximately half of the pelvic washing specimens during or after but not before robot-assisted radical cystectomy. Higher residual cancer cell levels were associated with aggressive variant histology and cancer recurrence. Verifying the feasibility of using residual cancer cells as a novel biomarker for recurrence requires larger cohorts.
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No direct or indirect commercial, personal, academic, political, religious or ethical incentive is associated with publishing this article. ROBOT-ASSISTED radical cystectomy was implemented to improve perioperative outcomes without jeopardizing oncologic efficacy. 1 Irrespective of the surgical approach local recurrence develops in approximately 18% of the patients who undergo RARC, in the majority within the first 2 years after surgery. 2 Recurrent urothelial carcinoma has been reported at abdominal wound and/or port sites, suprapubic tube sites, in the pelvic cavity (the resection bed) and on the psoas muscle. The exact pathogenesis of bladder cancer recurrence has not been fully elucidated. Even after radical cystectomy with a negative surgical margin the recurrent rate remains high and correlates with the stage and aggressiveness of the primary tumor. 6, 7 This suggests the existence of residual cancer cells such as preexisting micrometastatic tumor foci, as indicated by patterns of T-cell infiltration and tumor associated antigen in nonneoplastic tissues around cancer 8 or tumor cells spilled during the surgical procedure. 9 During RARC pneumoperitoneum may contribute to tumor dissemination, possibly by inhibiting the local peritoneal immune response by CO 2 or solely by the fluctuation in pressure. 10, 11 There is a pressing need for an accurate methodology to detect and quantify residual cancer cells, and stratify the relative risks, whether caused by tumor spillage during surgery and/or preexisting micrometastatic clones.
In the current study we investigated whether low level residual cancer cells may still exist when the surgical margin is pathologically negative, and whether they potentially contribute to bladder cancer recurrence. To detect low level residual cancer cells we chose a method based on high throughput sequencing, which has been shown to be a robust method to detect circulating tumor cells or cell-free tumor DNA. 12 The current method has 2 phases, including 1) identifying patient specific, somatically acquired mutations from the primary tumor by comparing it with the matched germline sample using conventional whole exome sequencing and 2) resequencing a small number of select mutations at much higher coverage to identify low level residual cancer cells in pelvic washes. Computational error suppression was implemented to filter out errors due to sequencing artifact. 13 The accuracy of the method was further confirmed in spike-in experiments.
We applied this methodology to identify residual cancer cells in intraoperative pelvic washes using patient specific (primary tumor specific) somatic mutations ( fig. 1, a and b) and explore the potential association of residual cancer cells with cancer recurrence and other clinical variables.
METHODS

Patient Selection
Enrolled in this study were 40 patients who underwent RARC and PLND as performed by a single surgeon (KAG) at Roswell Park Comprehensive Cancer Center (IRB protocols I-258714 and I-160009). The technique of RARC and intracorporeal ileal conduit formation was previously reported. 14, 15 All patients were evaluated and followed in compliance with the NCCN GuidelinesÒ.
Sample Collection
Intraoperative pelvic irrigations (washes) were collected at Tf1 before RARC, Tf2 after RARC, Tf3 after PLND and Tf4 suction ( fig. 1, a and c) . The supplementary methods (https://www.jurology.com) show details. An additional wash of Tf5 filter was collected in patient 30. Peripheral blood samples were collected before and after RARC, and after PLND.
Residual Cancer Cell Quantification
WES was performed to identify patient specific somatic mutations. UTS was performed to sequence 12 to 17 select mutations per patient in all specimens ( fig. 1, b) . The supplementary methods (https://www.jurology.com) provide detailed descriptions of the WES and UTS experimental methods, and analytical procedures identifying somatic mutation and calculating the RCCF.
In each patient the pRCCF was considered the highest RCCF observed in pelvic washes at any 1 of the 3 time points before RARC, after RARC, after PLND or in the suction fluid. This was compared with clinical and pathological variables, including tumor stage, lymph node status, positive surgical margins and histology as well as cancer recurrence, to determine associations.
RESULTS
Study Cohort
We initially enrolled 40 consecutive patients who underwent RARC. Before the current next generation sequencing based study we first investigated pelvic washes with conventional methods, such as cytology with immunohistochemistry and mRNA markers. However, we were unable to reliably detect residual cancer cells due to limited sensitivity (data not shown).
The current study included the 17 patients in whom primary tumor samples were available, which was required to identify patient specific mutations (see table) . All patients received a multidisciplinary consultation for neoadjuvant chemotherapy and 6 of the 17 patients underwent that treatment. All patients received an intracorporeal ileal conduit. No inadvertent entry into the bladder was observed, and the ureters and the urethra were clipped before removal in all cases.
Other than 1 SCC in patient 14 the other 16 patients had a hgUC primary histology, including 4 with variant histology such as plasmacytoid, squamous or glandular differentiation. All tumors had negative surgical margins.
Somatic Mutation Identification
WES was performed on the primary tumor and the matched blood DNA (germline DNA) in all 17 patients. The supplementary results, and supplementary tables 1 and 2 (https://www.jurology.com) show the WES mapping summary, the coverage statistics and the mutational landscape. Several patients had a few somatic mutations and most identified mutations had a low VAF (supplementary results figs. 1 to 3, https://www.jurology.com), indicating possible low tumor purity or significant heterogeneity, or tumorigenesis processes driven by other alterations such as copy number or structural variations. Since identifying residual cancer cells by targeted sequencing relies on tracing specific mutations identified by WES that are clonal rather than subclonal, in qualified patients at least 12 high VAF mutations (defined as 0.3 or greater) were identified, which excluded 7 from further analysis ( fig. 2, a) . The remaining 10 tumors included 1 SCC and 9 hgUCs. Four hgUCs had variant histology. TP53 was mutated in all 5 cases with more aggressive histology (SCC or hgUC with variant histology) but only in 3 of the 5 of the remaining tumors. Mutations in several genes showed a potential pattern of being group specific in the current cohort, including PIK3CA (3 of 6 in recurrent cases only), KRAS and MYCN (each 2 of 4 in nonrecurrent cases only) ( fig. 2, b) .
Residual Cancer Cells
Quantification. Figure 1 , b and c summarizes the design and statistics of UTS panels. In each patient 12 to 17 high VAF mutations (greater than 30% on WES) were selected as markers of residual cancer cells (supplementary table 3 , https://www.jurology. com). They were sequenced to a minimum of Â50,000 coverage in the primary tumor (1), blood (2 or 3), pelvic washes (3 or 4) and spike-in samples (4 or 6). Using the first patient (patient 10) as an example for illustration we selected 12 mutations as markers, which were sequenced in all samples, including the spike-in in 4, the primary tumor in 1, and blood and pelvic washes in 3 each. VAFs were elevated markedly to varying levels in the spike-in samples, VAFs in all 3 patient 10 blood samples were at baseline and VAFs were elevated in 1 pelvic washing sample after RARC (supplementary fig. 4 , https://www.jurology.com).
After calculating RCCF the spike-in samples demonstrated high accuracy compared to the designed spike-in percent, including 10.11% vs 10% in spike-in sample 4, 4.86% vs 5% in 3, 0.89% vs 1% in 2 and 0.08% vs 0.1% in 1 ( fig. 3, a) . The RCCF pelvic washing sample after RARC was 0.27%. Patient 32 was excluded from analysis due to possible sample contamination which was identified with spike-in controls. In the 3 spike-in controls with the highest mixing ratio (10%, 5% and 1%, respectively), the relative errors were fivefold to tenfold higher in patient 32 than any other patient (supplementary fig. 5 , https://www.jurology.com). The final analysis cohort included the remaining 9 patients (supplementary fig. 6 , https://www.jurology.com).
Pattern. Figure 3 , b shows the residual cancer cell levels measured by RCCFs in blood and pelvic washes in all patients in the final analysis cohort. Of the 17 blood samples after RARC and after PLND 16 were negative for residual cancer cells except for 1 sample from patient 30 after PLND. In that case residual cancer cells were present at an extremely low level (RCCF 0.02%). All 7 available pelvic washes before RARC were negative for residual cancer cells. After RARC 7 of 8 pelvic washes contained detectable residual cancer cells with the RCCF ranging from 0.02% to 0.63%. After PLND 3 of 9 pelvic washes were positive for residual cancer cells. The suction fluid was positive in 4 of the 9 patients, including patient 16 with no other residual cancer cell positive wash.
Altogether 14 of the 26 pelvic washes collected during or after surgery were positive compared with 0 of 7 collected before RARC. Seven of the 8 after RARC washes were positive compared to 3 of 9 PLND washes, which was a significantly higher portion (p <0.05). Eight of the 9 patients had at least 1 tumor positive washing. The pRCCF, defined as the highest observed RCCF among all pelvic washes, ranged from 0.07% to 0.64%.
Peak Relative Cancer Cell Fraction Association with
Clinical Variables. To determine whether the detected pRCCF correlated with clinical and histopathological variables we compared the pRCCF to tumor stage, histology, lymph node status, surgical margin and recurrence ( fig. 4, a) . A striking association was found between the pRCCF and tumor histology. When ranked by the pRCCF, the 5 highest pRCCF cases were exclusively associated with aggressive histologies. The highest pRCCF of 0.64% was found in patient 14, the only patient with a primary SCC histology, which was more aggressive than hgUC.
Of the remaining 8 hgUC cases the 4 with the highest pRCCFs all demonstrated aggressive variant histology, which was not found in the remaining 4 hgUC cases with lower pRCCFs. Overall the pRCCFs were significantly higher in patients with aggressive histology (SCC or hgUC with variant histology) than in patients with hgUC without variant histology (median 0.47 vs 0.12, Wilcoxon test p <0.01).
Despite our small sample size the current results suggest a potential association between the pRCCF and recurrence status. Recurrence developed within 2 to 16 months (median 5.5) after RARC in 6 of the 7 patients with a high pRCCF (greater than 0.1%) while there was no recurrence in the 2 patients with a low or negative pRCCF during followup between 18 and 24 months. Only patient 30 with a pRCCF without recurrence had a renal mass 3.6 months after surgery. This was later diagnosed as primary renal cell carcinoma and, therefore, was considered an independent primary tumor. Only this patient had a positive blood sample after PLND and all 3 washes were positive for residual cancer cells.
In this patient we tested an additional sample from an air exhaust filter of the peritoneal cavity, which was also positive with a low 0.04% RCCF (data not shown). Remarkably patients 33 and 20 with higher grade (T3a) disease but low or negative pRCCF did not experience recurrence but recurrence developed in patients 10 and 15 with lower stage disease (Ta and T2b, respectively) and a high pRCCF. Of patients 28, 33 and 20 with the same stage and histology (T3aN0 and hgUC with no secondary histology) only patient 28 with a high pRCCF experienced a later recurrence. Additionally, no correlation was found between pRCCF and the time from cystectomy to recurrence (fig. 4, b) .
DISCUSSION
Despite recent advances in neoadjuvant chemotherapy and the aggressive management of bladder cancer more than half of the patients with muscle invasive bladder cancer experience recurrence with a significant adverse impact on survival. 2, 16 Prior studies showed that recurrence was associated with disease related variables and surgery related factors. 17 Breaches of oncologic surgical principles and laparoscopy related factors have also been implicated in local disease recurrence.
10, 18 However, recent studies failed to show any association between the approach to RC and recurrence. 19, 20 This suggests that recurrence is associated with disease related factors rather than technical (laparoscopy related) factors. 16 The lack of identification of residual cancer cells by conventional methods in patients who later presented with recurrence suggests that there is an extremely low abundance of residual cancer cells or they have already disseminated to distant sites by the time of surgery. In this study using ultradeep sequencing we detected residual cancer cells in pelvic washes collected after RARC and after PLND but not before RARC. All patients had negative surgical margins and most had negative lymph nodes. These findings suggest that residual cancer cells may still be detected using more sensitive methods even in patients who were cleared by conventional markers.
The essential question is the source of residual cancer cells. Do these cells represent synchronous or preexisting metastases, or iatrogenic dissemination due to surgical failure which could give rise to metachronous metastasis? The 2 hypotheses are accidental tumor spillage and preexisting micrometastases ( fig. 5) . Our results suggest that the association observed between a high pRCCF and aggressive histology may indicate that pRCCF levels may be determined by tumor biology rather than by random spillage. The fact that residual cancer cells were undetected before RARC may suggest that micrometastases were sequestered beneath the intact peritoneum but became accessible after disruption of the peritoneum and exposure during surgery of the tissue structures beneath it (supplementary fig. 7 , https://www. jurology.com). No conclusions can be made due to our limited sample size.
Furthermore, unlike previous reports of an increased number of circulating tumor cells in blood after surgery presumably caused by spillage, 21 we found almost all blood samples after RARC and after PLND were negative for residual cancer cells, suggesting that tumor cells were not shed into the circulation.
Conventional markers to identify residual cancer include such findings as positive surgical margins or lymph nodes. However, the current method based on ultradeep sequencing has the potential to be used to develop a new molecular margin-free concept to help identify patients at high risk for the progression of bladder and other cancers with a high recurrence rate after surgery. 22 In this study the pN stage and variant histology had good accuracy but poor sensitivity to predict recurrence since 6 and 4 of the 9 patients did not have positive lymph nodes or aggressive histology, respectively. Further, in all 9 patients the surgical margins were negative and so did not provide any predictive value. Potential stratification using pRCCF could be especially useful in these patients without an indication of residual cancer according to conventional markers.
We consider the current study to be a proof of principle study due to our small sample size. Future studies in a larger number of patients including more complete coverage of different subtypes, stages and histologies would provide a more comprehensive understanding of the biological mechanisms responsible for residual cancer cells under different clinical conditions and confirm the relationship of residual cancer cells with disease recurrence. The current cutoff of a pRCCF greater than 0.1% in patients considered to have a high pRCCF might also need to be optimized with additional clinical variables in larger patient cohorts.
The design of targeted sequencing was based on high VAF mutations, which are more likely to be clonal rather than subclonal. Although this strategy reduced the chance of potential false-negative findings due to tumor heterogeneity, it is also more difficult to apply the technique in tumors with low purity or a low mutation burden.
Lastly, the current detection method based on whole exome sequencing and ultradeep targeted sequencing was optimized for maximum sensitivity but requires a long turnaround time and high cost. These factors would need to be improved for potential future clinical usefulness. Also, the identified patterns of residual cancer cells suggest that they are unlikely to be caused by random tumor spillage during surgery but probably indicate preexisting infiltrating micrometastatic tumor clones which clearly reflect the aggressiveness of the tumor. If confirmed by larger future studies, these findings will pave the road for the development of novel approaches using the measurement of residual cancer cells as highly sensitive biomarkers to predict recurrence. Such prognostic information might stratify patients who would benefit from intraperitoneal chemotherapy, similar to ovarian, gastric and colorectal malignancies. 
CONCLUSIONS
This proof of principle study based on a limited patient cohort demonstrated the feasibility of using ultradeep sequencing to achieve accurate quantification of residual cancer cells. The study revealed a potential association with histology and cancer recurrence. In this proof of principle study Wei et al found that residual cancer cells could be detected and quantified in pelvic washing using a 2-step sequencing approach. Nine of 17 patients were included in the final analysis cohort. Seven patients were excluded from study due to low variant allele fraction mutations and 1 was excluded due to possible sample contamination. Higher levels of residual cancer cells were associated with aggressive variant histology and cancer recurrence. Of note, 8 of the 9 patients included in the final analysis cohort had pT3/pT4/node positive bladder cancer. It is also important to note that residual cancer cells were detectable only in pelvic washes collected after robotic assisted radical cystectomy and after lymph node dissection but not before robotic assisted radical cystectomy. Almost all blood samples were negative for residual cancer cells. Although additional studies are required to clearly define the source of residual cancer cells, disruption of the peritoneum during the surgical procedure and the presence of extravesical disease likely contributed to residual cancer cell detection in pelvic washes. The RAZOR trial showed that robotic assisted radical cystectomy was noninferior to open radical cystectomy for 2-year progression-free survival. 1 It will be of great interest to compare the residual cancer cell detection rate in pelvic washes between robotic assisted and open radical cystectomy in future studies.
Sumit Isharwal
Department of Urology
University of Virginia Charlottesville, Virginia
